Other studies have shown that certain biomarkers related to plaque stability, such as soluble suppressor of tumorigenicity (sST)-2, interleukin 33 (IL-33), and soluble fibrinogen-like protein 2 (sFgl2), can increase the differentiation of Treg cells within plaques, promote the shift from Th1 to Th2 cells, delay the progression of atherosclerosis, and exert a protective effect [93,94,95,96]. This evidence concerns the gene IL33 and atherosclerosis.